Cantor Fitzgerald Reiterates a 'Buy' on Sunesis Pharmaceuticals (SNSS); Market Potential for Vosaroxin
Tweet Send to a FriendGet Alerts SNSS Hot Sheet
Price: $5.46 +0.92%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade SNSS Now!
Cantor Fitzgerald reiterates a 'Buy' on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) price target raised to $8.00.
Analyst, Mara Goldstein, said, "Following a planned interim analysis of the VALOR study, Sunesis will expand the patient enrollment of the study by 225 patients. This news suggests that the trial is trending in the "promising zone" and thus represents a positive outcome of the analysis. With this major milestone now behind the company, the shares should be free to trade on the likelihood of the trial and the market potential for vosaroxin."
"While investment focus is centered on VALOR and vosaroxin, licensed products represent a source of upside. MLN2480 is a pan RAF-inhibitor being developed by Millennium Pharmaceuticals (Takeda), and Sunesis has an option to opt-in to development after Phase I. In addition, the Biogen Idec (Nasdaq: BIIB) licensing deal is beginning to get some visibility, as Sunesis received a milestone payment from this collaboration in 2Q:12."
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $2.64 yesterday, with a 52 week range of $1.01-$3.57.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Mara Goldstein, said, "Following a planned interim analysis of the VALOR study, Sunesis will expand the patient enrollment of the study by 225 patients. This news suggests that the trial is trending in the "promising zone" and thus represents a positive outcome of the analysis. With this major milestone now behind the company, the shares should be free to trade on the likelihood of the trial and the market potential for vosaroxin."
"While investment focus is centered on VALOR and vosaroxin, licensed products represent a source of upside. MLN2480 is a pan RAF-inhibitor being developed by Millennium Pharmaceuticals (Takeda), and Sunesis has an option to opt-in to development after Phase I. In addition, the Biogen Idec (Nasdaq: BIIB) licensing deal is beginning to get some visibility, as Sunesis received a milestone payment from this collaboration in 2Q:12."
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $2.64 yesterday, with a 52 week range of $1.01-$3.57.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Wells Fargo Downgrades Aruba Networks (ARUN) to Market Perform
- Compass Point Boosts Numbers on RLJ Lodging Trust (RLJ)
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
